About Us

News

      FindCure Biosciences (ZhongShan) Co., Ltd. was established in December 2019 by Dr. Xi Ning, a national specially-appointed expert, and Professor Yuan Xueli, a clinical oncology specialist. It is a high-tech innovative biopharmaceutical enterprise with outstanding independent research and development capabilities as its core driving force.

      FindCure possesses comprehensive capabilities in preclinical R&D, translational medicine, and clinical research, while strategically focusing on two major tracks—immuno-oncology and nuclear medicine—targeting areas with significant unmet clinical needs. Its vision is to develop breakthrough First-in-Class or Best-in-Class drugs for the global market.

      The Company's lead immuno-oncology pipeline asset is currently being evaluated in a Phase II clinical trial in combination with tislelizumab. Two nuclear medicine pipeline programs, both globally leading and possessing Best-in-Class potential, have advanced into investigator-initiated clinical trials (IITs), demonstrating excellent tumor targeting and rapid metabolic clearance. The first nuclear medicine drug is expected to be submitted for marketing authorization in 2028, with several additional nuclear medicine programs poised to enter clinical development in the near future.